Editorials

Selective clinical trial reporting: betraying trial participants, harming patients

BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2753 (Published 10 June 2015) Cite this as: BMJ 2015;350:h2753
  1. Sidney M Wolfe, founder and senior advisor
  1. 1Public Citizen’s Health Research Group, 1600 20th Street NW, Washington, DC 20009, USA
  1. Correspondence to: swolfe{at}citizen.org

Reporting biases found in trials of cardiovascular devices

Reporting biases in published trials were first identified in 1986.1 Published randomized studies of combination chemotherapy compared with treatment with an alkylating agent as first line treatment for ovarian cancer showed a significant survival advantage for combination chemotherapy. Unpublished cancer trial registry data from the same studies, however, showed no such advantage.2 Similarly, in the treatment of multiple myeloma, registry data suggested a smaller survival advantage for combination chemotherapy (over prednisone and an alkylating agent) than the results of published studies. The author who reported the discrepancy concluded that his findings “demonstrate the value and importance of an international registry of all clinical trials.”1 Subsequent evidence for biased and selective reporting included prompt or delayed publication depending on whether trial results were positive or negative3 and more favorable results and conclusions in published studies funded by industry than in those funded independently.4

The linked paper by Chang and colleagues (doi:10.1136/bmj.h2613) shows …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe